Tag Archives: Research Funding

Dementia Moonshot Report: Research Priorities and Costs (Alzheimer’s Research UK)

Posted on January 25, 2020 by Dementia and Elderly Care News

Summary Alzheimer’s Research UK (ARUK) have released a brief report on six research priorities, which are: Achieving earlier detection of diseases which may cause dementia, (ideally by 10-15 years), to enhance development of new treatments / interventions for people most … Continue reading →

Posted in Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest | Tagged Accelerating Alzheimer's Research and Drug Development, Accelerating Detection of Disease, Accelerating Detection of Disease (ADD) Challenge, Accelerating Detection of Disease Programme, Alzheimer's and Dementia: Translational Research and Clinical Interventions (TRCI), Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Dementia Attitudes Monitor, Alzheimer’s Research UK’s Drug Discovery Alliance, Awareness, Awareness Raising, Benefits of Detection and Early Intervention, Benefits of Early Detection, Biomarker Development, Biomarkers, Brain Health Clinics, Charity Research Support Fund, Cognitive Function and Ageing Study II, Cross-Funder Review, Dementia Access Taskforce, Dementia Consortium, Dementia Moonshot, Dementia Prevalence, Dementia Prevention, Dementia Research, Dementia Research and Drug Development, Dementia Research Funding, Dementia Research Priorities, Dementia Risk Reduction, Dementia Risk Reduction and Prevention, Dementia Translational Medicines Accelerator, Dementia: Prevalence and Detection, Dementias Platform UK, DPUK: Dementias Platform UK, Dr Helen Beaumont: Alzheimer’s Research UK Champion, Drug Development for Alzheimer's Disease, Drug Discovery Alliance, Drug Discovery Institutes, Drug Target Validation, Early Detection of Neurodegenerative Diseases, Economic Impact of Dementia, Global Impact of Dementia, Global Leadership, Government Research Funding, Grand Challenge on Artificial Intelligence and Data, Helen Stokes-Lampard: Chair of RCGP, Hilary Evans: Chief Executive of Alzheimer’s Research UK, Impact of Dementia, Impact of Dementia (Statistics), Impact of Dementia in UK, Life Sciences Industrial Strategy, Life-Changing Treatment for Dementia by 2025 (Moonshot Aim), Medical Research Charities, Mike Gooley Trailfinders Charity Prevention and Risk Reduction Fund, Modifiable Risk Factors, Multi-Morbidities, Multi-Morbidity, No Time to Lose: An Action Plan for Dementia (ARUK), Participation in Research, Patient Involvement in Research, Potential Drug Targets, Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Professor Jamie Waterall: National Lead for Cardiovascular Disease at Public Health England, Professor Tara Spires-Jones: Alzheimer’s Research UK Grant Review Board, Research Funding, Research Priorities and Funding / Costs, Research Priorities and Networks, Social and Economic Impact of Dementia, Social and Economic Impact of Dementia in UK, Target Robustness Programme, Translational Medicines, Translational Research, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), UK Health Research Funding | Leave a comment

Plans for Meeting the Dementia Challenge by 2020 (DHSC)

Posted on February 24, 2019 by Dementia and Elderly Care News

Summary The Prime Minister’s Challenge on Dementia 2020 (2015) involved over 50 commitments for making England the best place in the world for dementia care, research and public dementia awareness in general. Feedback was subsequently collected, during 2018, concerning developments … Continue reading →

Dementia Research Centre in Wales (BBC News)

Posted on October 26, 2018 by Dementia and Elderly Care News

Summary A brief piece, from BBC News, on the work and aims of the £20 million Dementia Research Institute at Cardiff University. Full Text Link Reference Clarke, O. (2018). Fruit flies’ brains studied to help crack dementia. London: BBC Health … Continue reading →

Posted in BBC News, For Researchers (mostly), In the News, National, Quick Insights, UK, Universal Interest, Wales | Tagged BBC Health News, BBC Wales News, Biomarkers Research Programmes, Bioscience Careers, Brain Research Imaging Centre at Cardiff University (CUBRIC), Cardiff University, Dementia Action Plan for Wales: 2018-2022, Dementia Research, Dementia Research Careers, Dementia Research Institute (Cardiff), Dementia Research Institute (DRI), Dementia Research Institute at Cardiff University, Drosophila melanogaster, Fruit Flies, Genetic Research, Immune Pathways and Stem Cell (iPSC) Models of Neurodegenerative Disease, Immunology, Inflammation, Inflammatory Response, National Dementia Vision for Wales, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurodevelopmental Disorders: Abnormal Brain Development, Neuroinflammation, Neuroinflammation Research Cluster, Neuroscience, Research and Development, Research and Innovation, Research Careers, Research Commitment, Research Culture, Research Funding, Transgenic Drosophila, Vaughan Gething: Welsh Health Secretary, Welsh Government, Welsh Government Dementia Oversight of Implementation and Impact Group (DOIIG) | Leave a comment

A Further Set-Back for Progress in Dementia Drug Development? (BBC News)

Posted on January 11, 2018 by Dementia and Elderly Care News

Summary Drug company Pfizer is to cease activity in its neuroscience drug discovery programmes, which will impact on ongoing research into drugs for Alzheimer’s Disease and Parkinson’s Disease. Paradoxically the company does promise plans to create a new fund dedicated … Continue reading →

Posted in BBC News, For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Universal Interest | Tagged Big Pharma, Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Context, Global Outlook, International Organisations, International Programmes, Neurological Conditions, Neurological Disease, Neurological Disorders, Neuroscience Drug Discovery Programmes (Pfizer), Neuroscience Research, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding | Leave a comment

Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)

Posted on June 28, 2017 by Dementia and Elderly Care News

Summary The Deep and Frequent Phenotyping Study aims to discover new ways of diagnosing dementia, ideally decades before the symptoms become apparent in order to give future drug treatments the best chance of working. The Deep and Frequent Phenotyping Study … Continue reading →

Posted in Alzheimer's Society, BBC News, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, NIHR, Quick Insights, UK, Universal Interest | Tagged Ageing Population, Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Amnestic Mild Cognitive Impairment (a-MCI), Amnestic Mild Cognitive Impairment (aMCI), Applications of Big Data, BBC Radio, BBC Radio 4, BBC's World At One Programme, Big Data Analytics, Big Data Funding and Research, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Neuropsychological Test Automated Battery (CANTAB), Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Deep and Frequent Phenotyping Study (DFP), Deep and Frequent Phenotyping; Combinatorial Biomarkers of Dementia, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, DFP Study Team, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Gait and Cognition, Gait Changes, Gateway to Research (GtR), Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, Join Dementia Research, Join Dementia Research: Clinical Trials Matchmaker Service, Join Dementia Research: Recruitment Onto Dementia Studies, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurobiology of Aging (Journal), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Open Data and Big Data, Ophthalmological Assessments, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, PharmaCog Consortium, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Clare Mackay: Imaging Neuroscience at the University of Oxford, Professor Lynn Rochester: Clinical Ageing Research Unit at Newcastle University, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Publicly-Funded UK Big Data Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Screening Tools for Amnestic Mild Cognitive Impairment (a-MCI), Surrogate Biomarkers of Neurodegeneration, Translational Research, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology) | Leave a comment

MRC DRI Momentum Awards £4.3 Million For UK Dementia Research (MRC)

Posted on October 25, 2016 by Dementia and Elderly Care News

Summary Momentum Awards, which support the UK Dementia Research Institute (DRI). Today’s announcement involves six universities being awarded £4.3 million from the MRC to help develop UK-based dementia research. Judging from the press release, there appears to be a serious … Continue reading →

Posted in Commissioning, For Researchers (mostly), In the News, National, Quick Insights, UK, Universal Interest | Tagged Autism, Autism Spectrum Disorder (ASD), Biomarkers, Biomarkers Research Programmes, Bioscience Careers, Cardiff University, Computational Approaches to Discovery of Behavioural Signatures, Cross-Disciplinary Interfaces Exploring Emerging Scientific Opportunities, Dementia Research, Dementia Research Careers, Dementia Research Institute (DRI), Dr Kathryn Adcock: Head of Neurosciences and Mental Health at MRC, Epilepsy, Frontiers in Neuroscience, High Risk-High Payoff Research Projects (sic) [For Whom?], Human Brain Cell Types, Immune Pathways and Stem Cell (iPSC) Models of Neurodegenerative Disease, Institute of Psychiatry Psychology and Neuroscience (IoPPN), Kings College London, Maurice Wohl Clinical Neuroscience Institute, Momentum Awards, MRC Centre for Neurodevelopmental Disorders (King’s College London), MRC DRI Momentum Awards, MRC: Medical Research Council, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurodevelopmental Disorders: Abnormal Brain Development, Neuroinflammation, Neuroinflammation Research Cluster, Neuroscience, Neurovascular Dysfunction, Potential Drug Targets, Professor Oscar Marín: Director of Department of Developmental Neurobiology at Institute of Psychiatry Psychology and Neuroscience (IoPPN), Proteostasis, Proteostasis Dysfunction, Pump-Priming (Dementia Research), Recruitment of Research Leaders / Rising Stars, Research and Development, Research and Innovation, Research Careers, Research Commitment, Research Culture, Research Funding, Schizophrenia, Sensor Platform for Healthcare in a Residential Environment (SPHERE), Signalling Pathways, Treatment and Prevention Targets, UK Dementia Research Institute, University of Bristol, University of Edinburgh, University of Manchester, University of Oxford | Leave a comment

Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)

Posted on August 22, 2016 by Dementia and Elderly Care News

Summary The Deep and Frequent Phenotyping Study will explore improvements in biomarker research and the development of tests to detect Alzheimer’s Disease early on. This research programme will be funded by the National Institute of Health Research (NIHR) and the … Continue reading →

Posted in Alzheimer's Society, Charitable Bodies, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, National, NIHR, Quick Insights, UK, Universal Interest | Tagged Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Aridhia, AstraZeneca / MedImmune, Berry Consultants, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Cognition, Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Dr Rob Buckle: Director of Science Programmes at MRC, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Exprodo, Gait and Cognition, Gait Changes, Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, IXICO, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Ophthalmological Assessments, Optos, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Chris Whitty: Chief Scientific Adviser at Department of Health, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Sage Bionetworks, Surrogate Biomarkers of Neurodegeneration, Translational Research, TrialSpark, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology), West London Mental Health Trust / Imperial College London | 1 Comment

Tag Archives: Research Funding

Dementia Research Centre in Wales (BBC News)

A Further Set-Back for Progress in Dementia Drug Development? (BBC News)

Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)

MRC DRI Momentum Awards £4.3 Million For UK Dementia Research (MRC)

Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites